Holen Sie sich die Stockscreener-App
7.36
2.52%
-0.19
Vorhandelsmarkt:
7.40
0.04
+0.54%
Kyverna Therapeutics Inc Aktie (KYTX) Neueste Nachrichten
What is the Moat Score of Kyverna Therapeutics IncMarket Risk Report & Long Hold Capital Preservation Plans - baoquankhu1.vn
Stock Recap: Is AIRT a defensive stockWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
Aug Reactions: Can Kyverna Therapeutics Inc weather a recessionQuarterly Market Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Aug PostEarnings: Does Koninklijke Philips NV Depositary Receipt outperform in volatile marketsQuarterly Trade Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Income Plays: Can Kyverna Therapeutics Inc maintain sales growthJuly 2025 EndofMonth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Kyverna Therapeutics appoints Mayo Pujols as chief technology officer By Investing.com - Investing.com Nigeria
Kyverna Therapeutics Appoints New CTO to Drive CAR-T Manufacturing - TipRanks
Kyverna Therapeutics appoints Mayo Pujols as chief technology officer - Investing.com
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer - Quiver Quantitative
Fund Flows: Is Kyverna Therapeutics Inc stock trending bullishEarnings Trend Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Valuation Update: Is Scully Royalty Ltd on track to beat earningsGold Moves & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Street Watch: Can Kyverna Therapeutics Inc weather a recessionSell Signal & Safe Entry Zone Identification - baoquankhu1.vn
Macro Review: Can Kyverna Therapeutics Inc weather a recession2025 Earnings Surprises & High Return Trade Guides - baoquankhu1.vn
KYTX stock just surged 11% today – what is the connection with stiff person syndrome? - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Does Kyverna Therapeutics Inc outperform in volatile markets2025 Breakouts & Breakdowns & Fast Gain Stock Tips - baoquankhu1.vn
Volume Summary: Will Launch One Acquisition Corp benefit from AI trendsJuly 2025 Closing Moves & Weekly Sector Rotation Insights - baoquankhu1.vn
Risk Report: Will Kyverna Therapeutics Inc outperform tech stocksTrade Analysis Summary & Community Verified Trade Signals - baoquankhu1.vn
What’s Kyverna Therapeutics Inc.’s historical return2025 Technical Patterns & Technical Pattern Alert System - mfd.ru
What momentum indicators show for Kyverna Therapeutics Inc. stockPrice Action Analysis & Follow Top Performers in the Community - bollywoodhelpline.com
Will Kyverna Therapeutics Inc. stock see PE expansionWeekly Investment Report & Capital Efficiency Focused Strategies - bollywoodhelpline.com
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock - MSN
Nasdaq Moves: Can Kyverna Therapeutics Inc lead its sector in growth2025 Support & Resistance & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Aug Decliners: Can Kyverna Therapeutics Inc lead its sector in growthJuly 2025 Institutional & Low Risk High Reward Trade Ideas - baoquankhu1.vn
KYTX: First-in-class CAR-T therapy shows durable efficacy in autoimmune diseases, with commercial launch imminent - TradingView
KYTX: Mivcel delivers unprecedented outcomes in SPS and MG, with BLA filing and commercial launch imminent - TradingView — Track All Markets
Aug Catalysts: Will Kyverna Therapeutics Inc stock benefit from commodity pricesWeekly Trend Recap & Safe Entry Trade Reports - Bộ Nội Vụ
Will Kyverna Therapeutics Inc stock outperform value stocksWeekly Gains Summary & Entry Point Strategy Guides - Bộ Nội Vụ
Published on: 2026-01-13 22:22:40 - Bộ Nội Vụ
Kyverna Therapeutics Names Christi Shaw Executive Board Chair - The Globe and Mail
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference - The Manila Times
Cell therapy push targets stiff person syndrome and myasthenia gravis - Stock Titan
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO) and Xenon (XENE) - The Globe and Mail
Is Kyverna Therapeutics Inc. stock near bottom after declineRecovery Day Options & HOKA model picks for your routine - Улправда
What dividend safety score for Kyverna Therapeutics Inc. stock2025 Earnings Surprises & Daily Stock Momentum Reports - Улправда
How Kyverna Therapeutics Inc. stock trades before earnings2025 Biggest Moves & Weekly Stock Performance Updates - Улправда
Two-Year-Old Candid Looks To Move Autoimmune TCEs Into Phase II Development - Citeline News & Insights
What margin trends mean for Kyverna Therapeutics Inc. stockWeekly Trade Review & AI Based Buy and Sell Signals - ulpravda.ru
Will Kyverna Therapeutics Inc. stock recover faster than peersJuly 2025 Patterns & Smart Money Movement Tracker - Bộ Nội Vụ
Kyverna Therapeutics Inc Stock Analysis and ForecastPortfolio Risk Assessment & Free Strong Return On Assets - Early Times
Kyverna Therapeutics Inc trading halted, volatility trading pause - MSN
KYTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - accessnewswire.com
Kyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley - MSN
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - The Globe and Mail
Kyverna Therapeutics price target raised to $27 from $24 at Wells Fargo - MSN
Kyverna shares jump on strong results from SPS clinical trial - MSN
Kyverna Therapeutics (NASDAQ:KYTX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Kyverna’s Autoimmune CAR T Bet Rides On 2025–26 Trial Readouts - Finimize
The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stockSan Francisco Business Times - The Business Journals
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why - The Globe and Mail
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):